1. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJL. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 2006; 367: 1747-1757.
2. Organização Pan-Americana da Saúde. Indicadores básicos para a saúde no Brasil: conceitos e aplicações. Rede Interagencial de Informação para a Saúde – Ripsa – 2ª Edição – Brasília 2008. Disponível em: <http://tabnet.datasus.gov.br/cgi/idb2006/indicadores.pdf>. Acesso em: 08 Jan. 2011.
3. Donnan GA, Fisher M, Macleod M, Davis SM. Stroke. Lancet 2008; 371: 1612-1623.
4. Hankey GJ. Stroke: how large a public health problem and how can the neurologist help? Arch Neurol 1999; 56: 748-754.
5. Pasternak RC, Criqui MH, Benjamin EJ, Fowkes FG, Isselbacher EM, McCullough PA, Wolf PA, Zheng ZJ. Atherosclerotic Vascular Disease Conference: Writing Group I: Epidemiology. Circulation 2004; 109: 2605- 2612.
6. Sacco RL, Adams R, Albers G, Alberts MJ, Benavente O, Furie K, Goldstein LB, Gorelick P, Halperin J, Harbaugh R, Johnston SC, Katzan I, Kelly-Hayes M, Kenton EJ, Marks M, Schwamm LH, Tomsick T. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke. Stroke 2006; 37: 577-617.
7. Goldstein LB, Adams R, Alberts MJ, Appel LJ, Brass LM, Bushnell CD, Culebras A, Degraba TJ, Gorelick PB, Guyton JR, Hart RG, Howard G, Kelly-Hayes M, Nixon JV, Sacco RL. Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council. Stroke 2006; 37: 1583-1633.
8. Sitzer M, Muller W, Siebler M, Hort W, Kneimeyer HW, Janke L, Steinmtez H. Plaque ulceration and lumen thrombus are the main sources of cerebral microemboli in high-grade internal carotid artery stenosis. Stroke 1995; 26: 1231-1233.
9. Albuquerque LC, Narvaes LB, Filho JRH, Anes M, Maciel AA, Staub H, Rohde LE. Vulnerabilidade da doença aterosclerótica de carótidas: do laboratório à sala de cirurgia – parte I. Rev Bras Cir Cadiovasc 2006; 21: 127-135.
10. Moore WS, Quinones-Baldrich W, Krupski WC. Indications, surgical technique and results for repair of extracranial occlusive lesions. In: Rutherford RB editor. Vascular Surgery. 5th edition. Philadelphia: W.B. Saunders Company; 2000. pp1713-1730.
11. Imparato AM. Carotid endarterectomy: indications and techniques for carotid surgery. In: Ascher E, editor. Haimovici’s Vascular Surgery. 5th edition. Oxford: Blackwell Publishing; 2004. pp. 787-809.
12. Goldstein LB. Extracranial carotid artery stenosis. Stroke 2003; 34: 2767- 2773.
13. Howell SJ. Carotid endarterectomy. Br J Anaesth 2007; 99: 119-131. 14. Hobson RW 2nd, Mackey WC, Ascher E, Murad MH, Calligaro KD,
Perler BA. Management of atherosclerotic carotid artery disease: clinical practice guidelines of the Society for Vascular Surgery. J Vasc Surg 2008; 48: 480-486.
15. Bonamigo TP, Lucas ML. A endarterectomia carotídea é a melhor opção para os pacientes com doença carotídea. Arq Bras Cardiol 2008; 91: e29- e32.
16. North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Eng J Med 1991; 325: 445-453.
17. European Carotid Surgery Trialists’ Collaborative Group: MRC European Carotid Surgery Trial. Interim results for symptomatic patients with severe (70-99%) or with mild (0-29%) carotid stenosis. Lancet 1991; 337: 1235- 1243.
18. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. Endarterectomy for asymptomatic carotid artery stenosis. JAMA 1995; 273: 1421-1428.
19. Halliday AW for the Steering Committee and for the Collaborators. The Asymptomatic Carotid Surgery Trial (ACST): rationale and design. Eur J Vasc Surg 1994; 8: 703-710.
20. Golledge J, Greenhalgh RM, Davies AH. The symptomatic carotid plaque. Stroke 2000; 31: 774-781.
21. Hatsukami TS, Ferguson MS, Beach KW, Gordon D, Detmer P, Burns D, Alpers C, Strandness DE Jr. Carotid plaque morphology and clinical events. Stroke 1997; 28: 95-100.
22. Davies MJ. Stability and instability: two faces of coronary atherosclerosis. Circulation 1996; 94: 2013-2020.
23. Nighoghossian N, Derex L, Douek P. The vulnerable carotid artery. Stroke 2005; 36: 2764-2772.
24. Saam T, Hatsukami TS, Takaya N, Chu B, Underhill H, Kerwin WS, Cai J, Ferguson MS, Yuan C. The vulnerable, or high-risk, atherosclerotic plaque: noninvasive MR imaging for characterization and assessment. Radiology 2007; 244: 64-77.
25. Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM. Lesions from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2000; 20: 1262-1275.
26. Lusby RJ, Ferrel LD, Ehrenfeld WK, Stoney RJ, Wylie EJ. Carotid plaque hemorrhage. Its role in production of cerebral ischemia. Arch Surg 1982; 117: 1479-1488.
27. Mofidi R, Crotty TB, McCarthy P, Sheehan SJ, Mehigan D, Keaverry TV. Association between plaque instability, angiogenesis and symptomatic carotid occlusive disease. Br J Surg 2001; 88: 945-950.
28. Moody AR, Murphy RE, Morgan PS, Martel AL, Delay GS, Allder S, MacSweeney ST, Tennant WG, Gladman J, Lowe J, Hunt BJ. Characterization of complicated carotid plaque with magnetic resonance: direct thrombus imaging in patients with cerebral ischemia. Circulation 2003; 107: 3047-3052.
29. Burke AP, Kolodgie FD, Farb A, Weber DK, Malcom GT, Smialek J, Virmani R. Healed plaque ruptures and sudden coronary death: evidence
that subclinical rupture has a role in plaque progression. Circulation 2001; 103: 934-940.
30. Geroulakos G, Domjan J, Nocolaides A, Stevens J, Labropouos N, Ramaswami G, Belcaro G, Mansfield A. Ultrasonic carotid artery plaque structure and the risk of cerebral infarction on computed tomography. J Vasc Surg 1994; 20: 263-266.
31. Beach KW, Hatsukami T, Detmer PR, Primozich JF, Ferguson MS, Gordon D, Alpers CE, Burns DH, Thackray BD, Strandness DE Jr. Carotid artery intraplaque hemorrhage and stenotic velocity. Stroke 1993; 24: 314- 319.
32. Chambless LE, Folsom AR, Clegg LX, Sharrett AR, Shahar E, Nieto FJ, Rosamond WD, Evans G. Carotid wall thickness is predictive of incident clinical stroke: The Atherosclerosis Risk in Communities (ARIC) study. Am J Epidemiol 2000; 151: 478-487.
33. Hatsukami TS, Ross R, Polissar NL, Yuan C. Visualization of fibrous cap thickness and rupture in human atherosclerotic carotid plaque in vivo with high-resolution magnetic resonance imaging. Circulation 2000; 102: 959- 964.
34. Rohde LE, Lee RT. Pathophysiology of atherosclerotic plaque development and rupture: an overview. Semin Vasc Med 2003; 3: 347- 354.
35. Rotwell PM, Gutnikov SA, Warlow CP; European Carotid Surgery Trialist’s Collaboration. Reanalysis of the final results of the European Carotid Surgery Trial. Stroke 2003; 34: 514-523.
36. Virmani R, Kolodgie FD, Burke AP, Finn AV, Gold HK, Tulenko TN, Wrenn SP, Narula J. Atherosclerotic plaque progression and vulnerability to rupture. Angiogenesis as a source of intraplaque hemorrhage. Arterioscler Vasc Biol 2005; 25: 2054-2061.
37. Kwee RM, van Oostenbrugge RJ, Hofstra L, Teule GJ, Engelshoven JM, Mess WH, Kooi ME. Identifying vulnerable carotid plaques by noninvasive imaging. Neurology 2008; 70: 2401-2409.
38. Spagnolli LG, Mauriello A, Sangiorgy G, Fratoni S, Bonanno E, Schwarts RS, Piepgras DG, Pistolese R, Ippoliti A, Holmes DR Jr. Extracranial thrombotically active carotid plaque as a risk factor for ischemic stroke. JAMA 2004; 20: 1845-1852.
39. Redgrave JNE, Lovett JK, Gallager PJ, Rothwell PM. Histological assessment of 526 symptomatic carotid plaques in relation to the nature and timing of ischemic symptoms. The Oxford Plaque Study. Circulation 2006; 113: 2320-2328.
40. Naghavi M, Libby P, Falk E, Casscells SW, Litovsky S, Rumberger J, Badimon JJ, Stefanadis C, Moreno P, Pasterkamp G, Fayad Z, Stone PH, Waxman S, Raggi P, Madjid M, Zarrabi A, Burke A, Yuan C, Fitzgerald PJ, Siscovick DS, de Korte CL, Aikawa M, Juhani Airaksinen KE, Assmann G, Becker CR, Chesebro JH, Farb A, Galis ZS, Jackson C, Jang IK, Koenig W, Lodder RA, March K, Demirovic J, Navab M, Priori SG, Rekhter MD, Bahr R, Grundy SM, Mehran R, Colombo A, Boerwinkle E, Ballantyne C, Insull W Jr, Schwartz RS, Vogel R, Serruys PW, Hansson GK, Faxon DP, Kaul S, Drexler H, Greenland P, Muller JE, Virmani R, Ridker PM, Zipes DP, Shah PK, Willerson JT. From vulnerable plaque to vulnerable patient:
a call for new definition and risk assessment strategies: part I. Circulation 2003; 108: 1664-1672.
41. Chu B, Kampschulte A, Ferguson MS, Kerwin WS, Yarnykh VL, O’Brien KD, Polissar NL, Hatsukami TS, Yuan C. Hemorrhage in the atherosclerotic carotid plaque: a high-resolution MRI study. Stroke 2004; 35: 1079-1084.
42. Takaya N, Yuan C, Chu B, Saam T, Polissar NL, Jarvik GP, Isaac C, McDonough J, Natiello C, Small R, Ferguson MS, Hatsukami TS. Presence of intraplaque hemorrhage stimulates progression of carotid atherosclerotic plaques. A high-resolution magnetic resonance imaging study. Circulation 2005; 111: 2768-2775.
43. Takaya N, Yuan C, Chu B, Saam T, Underhill H, Cai J, Tran N, Polissar NL, Isaac C, Ferguson MS, Garden GA, Cramer SC, Maravilla KR, Hashimoto B, Hatsukami TS. Association between carotid plaque characteristics and subsequent ischemic cerebrovascular events. A prospective assessment with MRI – initial results. Stroke 2006; 37: 818- 823.
44. Altaf N, MacSweeney ST, Gladman J, Auer DP. Carotid intraplaque hemorrhage predicts recurrent symptoms in patients with high-grade carotid stenosis. Stroke 2007; 38: 1633-1635.
45. Albuquerque LC, Narvaes LB, Maciel AA, Staub H, Friedrich M, Filho JR, Marques MB, Rohde LE. Intraplaque hemorrhage assessed by high- resolution magnetic resonance and C-reactive protein in carotid atherosclerosis. J Vasc Surg 2007; 46: 1130-1137.
46. Kolodgie FD, Gold HK, Burke AP, Fowler DR, Kruth HS, Weber DK, Farb A, Guerrero LJ, Hayase M, Kutys R, Narula J, Finn AV, Virmani R. Intraplaque hemorrhage and progression of coronary atheroma. N Engl J Med 2003; 349: 2316-2325.
47. Buttari B, Profumo E, Petrone L, Pietraforte D, Siracusano A, Margutti P, Delunardo F, Ortona E, Minetti M, Salvati B, Riganò R. Free hemoglobin: a dangerous signal for the immune system in patients with carotid atherosclerosis? Ann N Y Acad Sci 2007; 1107: 42-50.
48. Ross R. Atherosclerosis – an inflammatory disease. N Engl J Med 1999; 340: 115-126.
49. Hansson GK, Libby P. The immune response in atherosclerosis: a double- edged sword. Nat Rev Immunol 2006; 6: 508-519.
50. EUROASPIRE: A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. Eur Heart J 1997; 18: 1569-1582.
51. Rothwell PM, Villagra R, Gibson R, Donders RC, Warlow CP. Evidence of a cause systemic of instability of atherosclerotic plaques. Lancet 2000; 355: 19-24.
52. Landmesser U, Hornig B, Drexler H. Endothelial function: a critical determinant in atherosclerosis? Circulation 2004; 109(21 Suppl 1): II27-33. 53. Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-874. 54. Mullenix PS, Andersen CA, Starnes BW. Atherosclerosis as inflammation.
Ann Vasc Surg 2005; 19: 130-138.
55. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105: 1135-1143.
56. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature 2011; 473: 317-325.
57. Stoll G, Bendszus M. Inflammation and atherosclerosis – novel insights into plaque formation and destabilization. Stroke 2006; 37: 1923-1932. 58. Nagase H, Visse R, Murphy G. Structure and function of matrix
metalloproteinases and TIMPs. Cardiovasc Res 2006; 69: 562-573.
59. Vu TH, Werb Z. Matrix metalloproteinasee: effectors of development and normal physiology. Genes Dev 2000; 14: 2123-2133.
60. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases structure, function, and biochemistry. Circ Res 2006; 92: 827-839.
61. Blankenberg S, Rupprecht HJ, Poirier O, Bickel C, Smieja M, Hafner G, Meyer J, Cambien F, Tiret L. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 2003; 107: 1579-1585.
62. Dollery CM, Libby P. Atherosclerosis and proteinase activation. Cardiovasc Res 2006; 69: 625-635.
63. Alvarez B, Ruiz C, Chacón P, Sabin JA, Matas M. Serum values of metalloproteinase-2 and metalloproteinase-9 as related to unstable plaque and inflammatory cells in patients with greater than 70% carotid artery stenosis. J Vasc Surg 2004; 40: 469-475.
64. Verhoeven B, Hellings WE, Moll FL, de Vries JP, Kleijn DPV, Bruin P, Busser E, Schoneveld AH, PasterkampG. Carotid atherosclerotic plaques in patients with transient ischemic attacks and stroke have unstable
characteristics compared with plaques in asymptomatic and amaurosis fugax patients. J Vasc Surg 2005; 42: 1075-1081.
65. Kunte H, Kunte G, Busch MA, Weichert W, Rückert RI, Harms L. Differences in carotid plaque content of macrophages, T cells and MMP-9 between patiens with embolic and hemodynamic cerebral ischemia due to symptomatic carotid stenosis. Atherosclerosis 2010; 211: 456-460.
66. Eldrup N, Gronholdt MM, Sillesen H, Nordestgaard BG. Elevated matrix metalloproteinase-9 associated with stroke or cardiovascular death in patients with carotid stenosis. Circulation 2006; 114: 1847-1854.
67. Taurino M, Raffa S, Mastroddi M, Visco V, Rizzo L, Torrisi MR, Faraglia V. Metalloproteinases expression in carotid plaque and its correlation with plasma leves before and after carotid endarterectomy. Vasc Endovascular Surg 2008; 41: 516-521.
68. Hermus L, Lefrandt JD, Tio RA, Breek JC, Zeebregts CJ. Carotid plaque formation and serum biomarkers. Atherosclerosis 2010; doi:10.1016/j.atherosclerosis.2010.05.013.
69. Newby AC. Metalloproteinases and vulnerable atherosclerotic plaques. Trends Cardiovasc Med 2007; 17: 253-258.
70. Loftus IM, Naylor AR, Goodall S, Crowther M, Jones L, Bell PR, Thompson MM. Increased matrix metalloproteinase-9 activity in unstable carotid plaques. A potential role in acute plaque disruption. Stroke 2000; 31: 40-47.
71. Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994; 94: 2493-2503.
72. Sapienza P, di Marzo L, Borrelli V, Sterpetti AV, Mingoli A, Cresti S, Cavallaro A. Metalloproteinases and their inhibitors are markers of plaque instability. Surgery 2005; 137: 355-363.
73. Sukhova GK, Schönbeck U, Rabkin E, Schoen FJ, Poole AR, Billinghurst RC, Libby P. Evidence for increased collagenolysis interstitial collagenases-1 and -3 in vulnerable human atheromatous plaques. Circulation 1999; 99: 2503-2509.
74. Nikkari ST, O’Brian KD, Ferguson M, Hatsukami T, Welgus HG, Alpers CE, Clowes AW. Interstitial collagenase (MMP-1) expression in human carotid atherosclerosis. Circulation 1995; 92: 1393-1398.
75. Nikkari ST, Geary RL, Hatsukami T, Ferguson M, Forough R, Alpers CE. Expression of collagen, interstitial collagenase, and tissue inhibitor of metalloproteinase-1 in restenosis after carotid endarterectomy. Am J Pathol 1996; 148: 777-783.
76. Nooijer R, Verkleij CJ, von der Thüsen JH, Jukema JW, van der Wall EE, van Berkel JC, Biessen EA. Lesional overexpression of matrix metalloproteinase-9 promotes intraplaque hemorrhage in advanced lesions but not at earlier stages of atherogenesis. Arterioscler Vasc Biol 2006; 26: 340-346.
77. Tziakas DN, Lazarides MK, Tentes IK, Georgiadis GS, Eleftheriadou E, Chalikias GK, Kortsaris A, Hatseras DI. Gelatinases [matrix metalloproteinase-2 (MMP-2) and MMP-9] induce carotid plaque instability but their systemic levels are not predictive of local events. Ann Vasc Surg 2005; 19: 529-533.
78. Ye S, Watts GF, Mandalia S, Humphries SE, Henney AM. Preliminary report: genetic variation in the human stromelysin promoter is associated with progression of coronary atherosclerosis. Br Heart J 1995; 73: 209– 215.
79. Ye S, Eriksson P, Hamsten A, Kurkinen M, Humphries SE, Henney AM. Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter which results in reduced gene expression. J Biol Chem 1996; 271: 13055–13060.
80. Humphries SE, Luong LA, Talmud PJ, Frick MH, Kesaniemi YA, Pasternack A, Taskinen MR, Syvänne M. The 5A/6A polymorphism in the promoter of the stromelysin-1 (MMP-3) gene predicts progression of angiographically determined coronary artery disease in men in the LOCAT gemfibrozil study. Lopid Coronary Angiography Trial. Atherosclerosis 1998; 139: 49–56.
81. Ghilardi G, Biondi ML, DeMonti M, Turri O, Guagnellini E, Scorza R. Matrix metalloproteinase-1 and matrix metalloproteinase-3 gene promoter polymorphisms are associated with carotid artery stenosis. Stroke 2002; 33: 2408–2412.
82. Rauramaa R, Vaisanen SB, Luong LA, Schmidt-Trucksass A, Penttila IM, Bouchard C, Töyry J, Humphries SE. Stromelysin-1 and interleukin-6 gene promoter polymorphisms are determinants of asymptomatic carotid artery atherosclerosis. Arterioscler Thromb Vasc Biol 2000; 20: 2657–2662. 83. Gnasso A, Motti C, Irace C, Carallo C, Liberatoscioli L, Bernardini S,
stromelysin gene promoter and common carotid geometry in healthy male subjects. Arterioscler Thromb Vasc Biol 2000; 20: 1600–1605.
84. Oostrom OV, Velema E, Schoneveld AH, Vries JPPM, Bruin P, Seldenrijk CA, Kleijn DPV, Busser E, Moll FL, Verheijen JH, Virmani R, Pasterkamp G. Age-related changes in plaque composition. A study in patients suffering from carotid artery stenosis. Cardiovasc Pathol 2005; 14: 126- 134.
85. Nanni S, Melandri G, Hanemmijer R, Cervi V, Tomasi T, Altimari A, Lent NV, Tricoci P, Bacchi L, Branzi A. Matrix metalloproteinases in premature coronary atherosclerosis: influence of inhibitors, inflammation, and genetic polymorphisms. Transl Res 2007; 149: 137-144.
86. Choudhary S, Higgins CL, Chen IY, Reardon M, Lawrie G, Vick GW, Karmonik C, Via DP, Morrisett JD. Quantitation and localization of matrix metalloproteinases and their inhibitors in human carotid endarterctomy tissues. Arterioscler Thromb Vasc Biol 2006; 26: 2351-2358.
87. Fiotti N, Altamura N, Fisicaro M, Carraro N, Uxa L, Grassi G, Torelli L, Gobbato R, Guarnieri G, Baxter BT, Giansante C. MMP-9 microsatellite polymorphism and susceptibility to carotid arteries atherosclerosis. Arterioscler Thromb Vasc Biol 2006; 26: 1330-1336.
88. Zhang B, Henney A, Eriksson P, Hamsten A, Watkins H, Ye S. Genetic variation at the matrix metalloproteinase-9 locus on chromosome 20q12.2–13.1. Hum Genet 1999; 105: 418–423.
89. Pöllänen PJ, Karhunen PJ, Mikkelsson J, Laippala P, Perola M, Penttilä A, Mattila KM, Koivula T, Lehtimäki T. Coronary artery complicated lesion area is related to functional polymorphisms of matrix metalloproteinase 9
gene: an autopsy study. Arterioscler Thromb Vasc Biol 2001; 21: 1446- 1450.
90. Pöllänen PJ, Lehtimäki T, Mikkelsson J, Ilveskoski E, Kunnas T, Perola M, Penttilä A, Mattila KM, Nikkari ST, Syrjäkoski K, Karhunen PJ. Matrix metalloproteinase 3 and 9 gene promoter polymorphisms: joint action of two loci as a risk factor for coronary artery complicated plaques. Atherosclerosis 2005; 180: 73-79.